

1 **Omega-3 & Aspirin Boost in Periodontal Therapy for Type II Diabetes: A Systematic**
2 **Review**

3 Emma Walker¹, John Franklin², Jonathan Robinson²

4
5 **Author Affiliations:**

6 ¹Clinician, myDentist, Eaglescliffe, UK, Coperate Dental, myDentist, Eaglescliffe,
7 Durham, UK TS16 0BU

8 ²Senior Lecturer in Research Methods, Teesside University, School of Health and Life
9 Sciences, Middlesbrough, UK, TS1 3BA

10

11 **Corresponding Author:**

12 Emma Walker Clinician, myDentist, Eaglescliffe, UK, Coperate Dental, myDentist,
13 Eaglescliffe, Durham, UK TS16 0BU, Email: walkerel@hotmail.com

14

15 Dr. Jonathan Robinson Teesside University, School of Health and Life Sciences,
16 Middlesbrough, UK, TS1 3BA, Email: J.Robinson@tees.ac.uk

17

18 **Acknowledgments, Funding, and Ethics**

19 No additional acknowledgments beyond those of the authors have been made, and no
20 funding was provided for this research. No ethical approvals were required for this
21 systematic review.

22

23 **Keywords:** Periodontal Therapy, Omega-3, Aspirin, Type 2 Diabetes, Systematic Review

24 **Abstract**

25 **Aim:** Omega-3 polyunsaturated fatty acids and aspirin are increasingly explored as
26 adjuncts in periodontal therapy for patients with type II diabetes, owing to their anti-
27 inflammatory properties. Despite preliminary evidence suggesting their effectiveness in
28 reducing periodontal inflammation and improving metabolic control, comprehensive
29 evaluations at the clinical level remain limited. This systematic review seeks to critically
30 assess the existing evidence to determine the efficacy of these agents in modifying
31 clinical, biochemical, and metabolic parameters in this high-risk patient group.

32

33 **Methods:** A comprehensive search was conducted across electronic databases,
34 including CINAHL, MEDLINE, PubMed, Embase, Dentistry & Oral Sciences Source, and
35 Cochrane Library, to identify relevant studies from inception to January 22, 2024. Included
36 studies were required to be randomised controlled trials and comprise both omega-3 and
37 aspirin as an adjunct to non-surgical treatment. Data extraction was completed
38 independently, and accuracy confirmed by a second reviewer. Data were synthesised
39 using the revised Cochrane risk of bias tool for randomised trials.

40

41 **Results:** A total of 76 records were identified, and three studies met the inclusion criteria.
42 One demonstrated a statistically significant difference in pocket depth, clinical attachment
43 gain and inflammatory markers compared to the control group, and two showed a
44 significant improvement in glycated haemoglobin levels.

45

46

47 **Conclusion:**

48 Omega-3 and aspirin combined have the potential to improve clinical parameters and
49 reduce inflammatory markers in the gingival crevicular fluid. Following non-surgical
50 periodontal treatment, this combination may enhance glycemic control and aid in
51 managing type II diabetes. This systematic review offers insights into the potential
52 effectiveness of omega-3 polyunsaturated fatty acids and aspirin as adjuncts to non-
53 surgical periodontal therapy in patients with type II diabetes and periodontitis. However,
54 current research is limited by small sample sizes and varied study designs. Consequently,
55 there is insufficient evidence to integrate this approach into clinical practice at present.

56

57 **Keywords:** Periodontal Therapy, Omega-3, Aspirin, Type 2 Diabetes, Systematic Review

58

59

60

61

62

63

64

65

66

67 1. INTRODUCTION

68 Periodontitis is an inflammatory disease that can lead to progressive destruction of the
69 surrounding periodontal tissues, leading to potential tooth loss.¹ Plaque formation is
70 needed to initiate periodontal inflammation; however, it is not sufficient to induce
71 periodontal destruction by itself.² Destruction is caused by an exaggerated immune-
72 inflammatory host response to the microbial challenge.² Periodontal pathogens in plaque
73 trigger a pro-inflammatory response involving the recruitment of neutrophils which leads
74 to a local release of reactive free radicals and enzymes which damage the host tissue.³
75 If there is a constant state of imbalance between the host's immune-inflammatory
76 response and excess bacterial plaque, then disease will occur.³

77
78 Severe periodontitis is the sixth most prevalent disease worldwide affecting nearly 750
79 million people.¹ The Adult Dental Health Survey for England, Wales, and Northern Ireland
80 identified 8% of adults have at least one pocket of ≥ 6 mm.⁴ Those experiencing severe
81 periodontitis may experience periodontal inflammation, loss of periodontal attachment,
82 bone loss and tooth mobility which can have a negative impact on daily life.⁵

83
84 Type II Diabetes Mellitus is a common metabolic disease characterised by a disorder in
85 insulin secretion, insulin resistance or a combination of both resulting in hyperglycaemia.⁶
86 Prolonged hyperglycaemia causes serious damage to multiple body systems causing
87 disease.⁵ The World Health Organisation estimated there were 422 million adults
88 worldwide with Type II Diabetes Mellitus.⁷ Chee et al.⁸ suggests a bi-directional
89 relationship exists between diabetes and periodontitis. Diabetes does not cause

90 periodontitis but increases the risk for periodontal diseases and in turn may exacerbate
91 worsening glycaemic control.³

92

93 Glycaemic control is measured by assessing the level of glycated haemoglobin (HbA1c)
94 in the blood, as hyperglycaemia causes glucose to irreversibly bind to the haemoglobin
95 molecule.⁵ HbA1c can be expressed as a percentage which indicates the amount of
96 glucose molecules absorbed onto haemoglobin.⁵ Alternatively, HbA1c can be reported in
97 mmols/mol. Non-diabetics have HbA1c levels around 5.5% (37mmol/mol).⁵ Type II
98 Diabetes Mellitus patients with HbA1C levels of <7.0% (53mmol/mol) show good
99 glycaemic control.⁵ Levels above >8-9% (64-75mmol/mol) indicate poor glycaemic
100 control. Complications of diabetes are linked to the level of glycaemic control; it has been
101 shown that the risk of diabetic complication reduces with each 1% reduction in HbA1c.⁵

102

103 Prolonged hyperglycaemia can cause excess glucose in the gingival crevicular fluid
104 (GCF).⁸ Bacteria thrive on sugar and enriched glucose-GCF may alter the bacteria
105 composition within the biofilm which can favour and influence the development of
106 periodontitis.⁹ Diabetics have an impaired neutrophil function, defective chemotaxis and
107 phagocytosis which enables bacterial persistence in the periodontal pocket increasing
108 destruction.³ Often patients have a hyper-responsive monocyte-macrophage phenotype
109 which can increase the production of pro-inflammatory cytokines and mediators.⁸
110 Elevated levels of pro-inflammatory cytokines accumulating in the GCF is related to
111 glycaemic control.⁸ Mealey et al.⁶ demonstrated Type II Diabetes Mellitus periodontal
112 patients with HbA1c levels >8% had double the amount of interleukin-1b (IL-1b) in the

113 GCF compared to Type II Diabetes Mellitus patients with HbA1c levels <8%. An increase
114 in other inflammatory mediators such as tumour necrosis factor- α (TNF- α) result in
115 increased periodontal inflammation, clinical attachment loss and bone loss.⁶

116
117 To our knowledge there have been no systematic reviews which have synthesised the
118 findings of studies investigating the use of omega-3 and aspirin in people with Type II
119 Diabetes Mellitus and periodontal disease. It is therefore the aim of this review to evaluate
120 the effectiveness of omega-3 and aspirin as an adjunct to NSPT in people with Type II
121 Diabetes Mellitus and periodontitis in decreasing clinical, biochemical, and metabolic
122 parameters.

123

124 **2. MATERIAL AND METHODS**

125

126 This Systematic review followed the Preferred Reporting Items of Systematic Reviews
127 and Meta Analyses (PRISMA) guidelines.¹⁰ The review protocol was registered with
128 PROSPERO, registration number: CRD42022341870 (22 July 2022) at:
129 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022341870

130

131 **2.1 Literature search strategy**

132 Table 1 presents the items using the PICO (participants/patient, interventions,
133 comparators, outcomes) format.

134

135 Table 1: Summary of PICO components

Table 1. PICO objectives.	
Items	Objective
Patient (P)	periodontitis with diabetes type II.
Intervention (I)	omega 3, aspirin.
Comparison (C)	non-surgical periodontal therapy and placebo
Outcome (O)	reduction in clinical, biochemical, and metabolic parameters, pocket depth (PD), clinical attachment level (CAL), glycated haemoglobin (HbA1c) and inflammatory markers.

136

137 **2.2 Criteria for Selecting Studies into the Review**

138 To be included in this review studies were required to meet the following criteria
139 (summarised in table 2): *Population*: Adults (18 years+) with a confirmed diagnosis of
140 both diabetes mellitus type 2 and periodontal disease; *Intervention*: assess the
141 combination of omega-3 and aspirin; *Comparison*: non-surgical periodontal therapy
142 (NSPT) and placebo groups; *Outcome*: assess clinical, biochemical, and metabolic
143 parameters, pocket depth (PD), clinical attachment level (CAL), glycated haemoglobin
144 (HbA1c) and inflammatory markers; *Types of Studies*: be randomised controlled trials.

145

146

147

148 Table 2: Summary of inclusion and exclusion criteria

	Inclusion criteria	Exclusion criteria
Population	Adults Type II diabetes Periodontal disease	Gingivitis
Intervention	Omega-3 and aspirin	N/A
Comparison	non-surgical periodontal therapy placebo	N/A
Outcome	Pocket depth Clinical attachment level Glycated haemoglobin (HbA1c)	N/A
Types of studies	Randomised controlled trial	Grey literature

149

150 **2.3 Search strategy**

151 An initial search was conducted by two reviewers (EW, JH) for published systematic
152 reviews followed by a comprehensive search of MEDLINE and PubMed to identify
153 relevant terms and citations. An extensive search was then conducted using MEDLINE,
154 PubMed, Embase, Dentistry & Oral Sciences Source, and CINAHL databases in August
155 2022. Box 1 shows an example of a MEDLINE search which was run in each database.
156 Box 1 provides an example of a MEDLINE search that was conducted in each database.
157 Hand searching was completed when a relevant study was found in the text and
158 references of the studies that were identified in the database search. On 22nd January
159 2024, all electronic searches were updated.

160

161

162

163 Box 1: Search terms and Boolean operators used in comprehensive search strategy.

[(periodontitis OR periodontal disease) AND (diabetes mellitus OR diabetic type 2 OR diabetic type II) AND (non-surgical periodontal therapy OR scaling OR debridement) AND (omega-3 poly unsaturated fatty acids OR omega 3 OR docosahexaenoic OR eicosapentaenoic) AND (aspirin OR asa OR acetylsalicylic)]

164

165 **2.4 Selection of studies**

166 One reviewer (EW) transferred the found studies to an Excel spreadsheet whereby all
167 duplicates were detected, deleted, and checked manually for accuracy. This was then
168 imported into Rayyan - a web and mobile app for systematic reviews
169 (<https://www.rayyan.ai/>,¹¹). Two reviewers (EW and JR) screened all abstracts, and then
170 full-text articles, independently and blindly using Rayyan, based on the PICO framework
171 and inclusion and exclusion criteria (see Table 2). Disagreements between the reviewers,
172 would have been discussed with a third reviewer - no disagreements were found. Cohen's
173 kappa statistic was calculated at each phase of the selection process (title and abstract,
174 and full text) to evaluate agreement between raters.¹²

175

176 **2.5 Data extraction and assessment of risk of bias**

177 The full-text of the selected articles were read and data extracted by one author (EW).
178 Extracted data included: characteristics of the study and population (i.e., age, sex);
179 definition of diabetes (i.e., type, glycaemic control); definition of periodontitis (i.e.,
180 moderate, severe); Intervention (i.e., type, duration) and control group (i.e., placebo

181 contents); and follow up time period and measured outcome parameters. Outcome
182 parameters were pocket depth (PD), clinical attachment level (CAL), glycated
183 haemoglobin (HbA1c), interleukin (IL-1 β) monocyte chemo-attractive protein (MCP) and
184 pentraxin (PTX3). Included studies were required to have one or more test groups and
185 follow up periods. Where data were reported in a box and whisker plot, the Digitizelt
186 software programme¹³ was used to extract data and converted into median interquartile
187 range. The included studies were assessed by one reviewer (EW) using a standard table
188 based on the revised Cochrane risk of bias 2.0 tool for randomised trials (RoB 2; ¹⁴).

189

190 **2.6 Data Synthesis**

191 The synthesis without Meta-Analysis (SWiM) guidelines were used to underpin the
192 synthesis approach.¹⁵ A narrative synthesis approach was used as the synthesis method
193 to summarise the outcome measures. Meta-analysis was not used in this case due to the
194 anticipated heterogeneity.


195

196 **3. RESULTS**

197 **3.1 Study Selection**

198 The search strategy identified 76 records, of which 11 were duplicates. Sixty-five were
199 screened by reviewing the titles and abstracts and 51 were excluded, and 8 were retrieved
200 for full text review. Three studies met the inclusion criteria (see Table 2). The selection
201 process is summarised in Figure 1. Cohen's kappa statistics measuring interrater
202 agreement for titles and abstracts, and full-text articles were 1 and 1, respectively.

203



204 Figure 1: PRISMA Flow Chart.

205

206

207 3.2 Study Characteristics

208 Included in this review are two blinded randomised controlled trials^{16,17}, and one
 209 randomised controlled trial.¹⁸ The population group consisted of males and females who
 210 were diabetic and had moderate to severe periodontitis. The included studies involved a
 211 total of 157 participants (range 40-75 per study), of which 98 participants were randomly
 212 assigned to an intervention group and 59 were assigned to the control group. The typical
 213 characteristics of the studies are shown in Table 3.

214

215 Table 3: Summary of papers

Study	Study Design	Country	Sample size Number Male/Female	Population Characteristics	Intervention	Control group	Follow up	Evaluated Parameters
Elwakeel & Hazaa., (2015).	RCT Double-blind Parallel groups	Egypt	40 Control group 10:10. Intervention group 10:10	Mean ± SD age: 40.05 ± 9, (Range 24-58 years) Periodontal Disease: Moderate-severe ≥14 natural teeth, at least 5 teeth with PD ≥ mm and CAL ≥ 4 mm Type II Diabetes with HbA1c between 7% and 8%	n = 20, NSPT+omega-3 1000mg 3 times a day+75 mg aspirin once a day, for 6 months	n = 20 NSPT + placebo (Placebo for aspirin: lactose tablet. placebo for x3 PUFAs: coconut oil) once day 6 months	0, 3, 6 months	PD, CAL, GI, PI, GCF levels of IL-1β and MCP, HbA1c levels
Castro dos Santos et al., (2020).	RCT Double-blind	Brazil	75 Control group 9:16 Intervention grp 1 9:16 Intervention grp 2 12:13	Mean ± SD age: G0: 54.9 ± 9.7, G1: 55.6 ± 8.3, G2: 54.4 ± 10.2 Periodontal Disease: Severe-generalised CP: at least 6 sites with PD and CAL ≥ 5 mm and BOP Type II diabetes treated with oral hypoglycaemic and/or insulin with HbA1c ≥ 6.5% to 11%	Group 1: (n = 25) NSPT+Omega-3 900mg +Aspirin 100 mg daily for 2 months after periodontal treatment Group 2: (n = 25) Omega-3 900mg+aspirin 100 mg daily for 2 months before periodontal treatment+ NSPT	n = 25 NSPT + placebo (Not Described) after NSPT 2 months	0, 3, 6 months	PD, CAL, Recession, BOP, PI, IL-1β inflammatory markers, HbA1c levels

Rampally et al., (2019).	RCT	India	42 unknown	Age range: 30-65 years. Periodontal disease: At least 4 teeth with PD \geq 5mm CAL \geq 4mm Type II diabetes taking metformin 500mg per day with HbA1c values \geq 6.5%	Group 1: (n = 14) NSPT + aspirin 75mg once daily for 90days Group 2: (n = 14) NSPT + Omega 3 fatty acids 500mg twice daily for 90 days	Group 3: (n = 14) NSPT placebo (empty gelatine capsule) +	0, 3 month	PD, CAL, GI, HbA1c levels, Pentraxin levels
--------------------------	-----	-------	-------------------	--	---	---	------------	---

216 **Key:** BOP: Bleeding on probing; CAL: Clinical attachment level; GCF: Gingival crevicular fluid; GI: gingival index;
 217 HbA1c: glycated haemoglobin; IL-1 β : Interleukin-1 β ; MCP: Monocyte chemo-attractive protein; NSPT: Non-surgical
 218 periodontal therapy; PD: probing depth; PI: plaque index; RCT: randomised controlled trial

219

220 3.3 Omega 3 and aspirin

221 Two studies investigated the effect of omega-3 and aspirin as an adjunct to NSPT.^{16,17}
 222 Whereas the third investigated these interventions administered separately.¹⁸ The control
 223 group in all three papers were given placebo tablets alongside NSPT for the specified
 224 time frames. Only two papers specified the contents of the placebo.^{16,18} The dosage of
 225 aspirin ranged between 75 - 100 mg daily and omega-3 ranged between 500 - 3000 mg
 226 daily in all. The duration of the administered intervention ranged between 2-6 months.

227

228 3.4 Non-Surgical Periodontal therapy

229 Elwakeel et al.¹⁶ performed NSPT with hand scalers and ultrasonic instrumentation in two
 230 sessions, over a two-week period. Whereas Castro dos Santos et al.¹⁷ provided this
 231 treatment over one session. Both studies reported NSPT was completed by a single
 232 periodontist who was blinded to the allocation groups at baseline, and each follow-up
 233 appointment. Oral hygiene instruction was given and reinforced at every visit. However,
 234 Rampally et al.¹⁸ did not report on how NSPT was performed and whether oral hygiene
 235 instruction was given.

236 **3.5 Clinical Parameters**

237 Two studies^{16,18} used a Williams probe whereas the third study¹⁷ used the UNC15 probe
238 to assess the periodontal condition. In each study, PD and CAL were recorded at baseline
239 and at each follow up. Two studies^{16,17} reported that clinical indices were recorded by the
240 same examiner, who remained blinded to allocation and had partaken in calibration
241 exercises (¹⁷: 92%; ¹⁶: k value 0.82). The test group in the study by Elwakeel et al.¹⁶
242 showed a significant decrease in PD and CAL compared to the control group ($p < 0.01$).
243 Two papers^{17,18} showed a significant improvement between all groups with regards to
244 clinical parameters but failed to establish a statistically significant difference between
245 control and test group (see Table 4). Bleeding on probing (BOP), plaque and gingival
246 indices were not collated for this systematic review due to insufficient data to compare for
247 each study.

248

249 **3.6 Biochemical effects**

250 Two studies^{16,17} reported the measurement of multiple inflammatory cytokines in the GCF
251 as IL-1 β and MCP were reported in both studies only this data was collated. IL-1 β
252 decreased over time in both studies. However, only one study¹⁶ showed a statistically
253 significant difference compared to the control group ($p < 0.01$). No significant differences
254 were detected in MCP concentration levels in Castro dos Santos et al.¹⁷, whereas
255 Elwakeel et al.¹⁶ detected a statistically significant difference ($p < 0.01$) in its MCP levels
256 at 3 and 6 months compared to baseline. Rampally et al.¹⁸ differed due to the absence of
257 measuring inflammatory cytokines, instead measuring plasma pentraxin (PTX3) which
258 belongs to the C-reactive protein. The greatest improvement was observed in Test group

259 2, followed by Test group 1 and both indicative of a statistically significant difference ($p <$
 260 0.001) compared to the CG (see Table 4).

261

262 3.7 Metabolic Parameters

263 HbA1c were measured at various time points as shown in table 4 for each study. There
 264 was a marked improvement in HbA1c values across all three studies; however, only one
 265 study¹⁷ demonstrated a statistically significant difference ($p < 0.05$) compared to the CG.

266

267 Table 4: Overview of results

Study	Outcome	TG1 0	TG1 3	TG1 6	TG2 0	TG2 3	TG2 6	CG 0	CG 3	CG 6
Elwakeel & Hazaa. [16].	PD (mm)*	5.7 ± 0.8	3.5 ± 0.51**	2.8 ± 0.52**	—	—	—	5.85 ± 0.99	4.55 ± 0.83**	3.8 ± 0.7**
	CAL(mm)*	6.05 ± 1.76	4.15 ± 1.53**	3 ± 1.78**	—	—	—	6.6 ± 1.19	5.1 ± 0.85**	4.2 ± 0.52**
	HbA1c*	7.6 ± 0.4	7.43 ± 0.37	6.99 ± 0.51	—	—	—	7.59 ± 0.33	7.14 ± 0.42	7 ± 0.4
	IL-1* (pg/mL)	259.8 ± 38.8	106.85 ± 31.94	65.65 ± 13.06**	—	—	—	268.65 ± 34.7	148.7 ± 41.59	92.1 ± 12.77**
	MCP* (pg/mL)	9.2 ± 1.0	6.29 ± 0.71	5.47 ± 0.83**	—	—	—	9.42 ± 1	7.86 ± 1.15	6.24 ± 0.42**
Castro dos Santos et al. [17].	PD (mm)*	3.3 ± 0.6	2.8 ± 0.4	2.9 ± 0.4	3.2 ± 0.5	3.1 ± 0.6	2.9 ± 0.4	3.3 ± 0.5	2.9 ± 0.4	2.9 ± 0.4
	CAL (mm)*	3.9 ± 0.8	3.5 ± 0.8	3.4 ± 0.8	3.8 ± 0.8	3.8 ± 1.0	3.5 ± 0.8	3.8 ± 0.6	3.5 ± 0.7	3.6 ± 0.6
	HbA1c*	8.14	—	7.63**	8.08	—	7.97	8.16	—	8.10
	IL-1°	2.36	1.95	2.04	3.03	2.32	0.82	1.6	3.30	245.29
	MCP°	311	888.6	342.6	202.5	646.9	303.92	538	514	319.1
	PD*	6.43 ± 0.51	4.43 ± 0.51	—	6.71 ± 0.47	4.71 ± 0.47	—	6.43 ± 0.51	4.43 ± 0.51	—

Rampally et al. [18].	CAL*	5.43 ± 0.51	3.43 ± 0.51	—	5.71 ± 0.47	3.71 ± 0.47	—	5.43 ± 0.5	3.43 ± 0.51	—
	HbA1c*	8.97 ± 1.46	6.98 ± 0.88**	—	8.10 ± 1.15	7.14 ± 1.21**	—	7.54 ± 0.82	7.25 ± 0.81	—
	Pentraxin*	359.13 ± 698.67	101.42 ± 72.31**	—	264.5 ± 497.5	76.63 ± 25.65**	—	721.3 ± 1934.03	212.44 ± 347.01	—

268 Key: CAL, Clinical attachment level, HbA1c, glycated haemoglobin A1c; IL-1, interleukin; MCP, monocyte
 269 chemoattractant protein. PD, Pocket depth, TG-Test Group. CG-Control group, ** indicates significant difference
 270 between TG and CG, - indicates data not available in paper.

271

272 3.8 Risk and quality assessment of bias

273 Of the three studies included in this systematic review, two scored a low risk of bias and
 274 one scored some concerns (see Table 5). Rampally et al.¹⁸ did not report on the
 275 randomisation process, allocation concealment, or blinding. Furthermore, the included
 276 studies only reported P-values and did not include confidence intervals or effect sizes.

277

278 Table 5: Risk of bias assessment of randomised clinical trials

Risk of bias	Elwakeel & Hazaa. [16]	Castro dos Santos et al. [17]	Rampally et al. [18]
1. Random sequence generation	+	+	?
2. Allocation concealment	+	+	+
3. Blinding or participants and personnel	+	+	?
4. Blinding of outcomes	+	+	+
5. Incomplete outcome data	+	+	+
6. Selective reporting	+	+	+
7. Other sources of bias	+	+	+
8. Bias	Low	Low	Some concerns
9. Reason	N/A	N/A	Some concerns about allocation and randomisation
Key: + = Low risk; ? = Risk not clear			

279 4. DISCUSSION

280 4.1 Summary of the evidence

281 This systematic review aimed to investigate the effect of omega-3 and aspirin as adjuncts
282 to non-surgical periodontal therapy (NSPT) in diabetic type II patients with periodontal
283 disease. The review yielded three main findings. Firstly, Elwakeel et al.¹⁶ reported a
284 statistically significant difference in periodontal clinical parameters and inflammatory
285 markers ($p < 0.01$) when NSPT was performed alongside adjunctive omega-3 and aspirin
286 compared to the control group. Secondly, Rampally et al.¹⁸ measured pentraxin levels
287 and demonstrated a statistically significant difference compared to a control group ($p <$
288 0.001). Finally, two studies^{17,18} showed a significant improvement in glycated
289 haemoglobin levels ($p < 0.05$) compared to the control group.

290

291 Clinical benefits of adjunct usage of omega-3 and aspirin have been observed in previous
292 studies. El-Sharkawy et al.¹⁹ proposed omega-3 and aspirin given for 6 months adjunct
293 to NSPT, documented a greater reduction in PD and CAL in the experimental group
294 compared to a control group. Similarly, Elwakeel et al.¹⁶ observed statistically significant
295 improvements ($p < 0.01$) in PD and CAL favouring the experimental group after 6 months.
296 In contrast, the remaining studies, despite showing an improvement in these parameters,
297 showed no significant difference between experimental and control groups. An
298 explanation could be due to the dosage of intervention given and the period of time within
299 which it was administered. In the included studies, the dosage of aspirin given daily
300 ranged between 75-100mg, whereas omega-3 varied greatly from 500-3000mg daily. The
301 time frame for the administered interventions in the three studies ranged from 2-6

302 months. This may explain why two of the papers did not yield a significant difference in
303 clinical parameters.

304

305 The concentration levels of pro-inflammatory cytokine IL-1 β were measured in two of the
306 included papers.^{16,17} These demonstrated an improvement between all groups for IL-1 β ;
307 however, only Elwakeel et al.¹⁶ showed a statistically significant reduction ($p < 0.01$)
308 compared to the control group. This supports the findings by Stadler et al.²⁰ whereby
309 NSPT alone was effective in decreasing GCF cytokine levels in periodontitis after 6
310 months. Alexander et al.²¹ supported the use of omega-3 and aspirin after periodontal
311 flap debridement and demonstrated a significant reduction in levels of IL-1 β after 6
312 months. Only one study measured pentraxin levels (PTX3) which belongs to the family of
313 C-reactive proteins (CRP).¹⁸ There was a significant difference ($p < 0.01$) in PTX3 levels
314 in both intervention groups compared to the control group. However, the improvement
315 significantly favoured the omega-3 group compared to the aspirin test group when
316 combined with NSPT. CRP serves as an activator for the complement system which
317 assists the innate immune system in the destruction of the periodontium. Telgi et al.²²
318 concluded that NSPT was effective in reducing CRP in GCF; however, this study was
319 conducted on healthy individuals without systemic disease. A more recent systematic
320 review showed dietary omega-3 is associated with lower inflammatory biomarkers in the
321 GCF among diabetics and is a useful therapy for other chronic inflammatory diseases
322 such as cardiovascular disease and rheumatoid arthritis.²³ Therefore, this highlights the
323 potential benefit of administering host modulation therapy in patients with risk factors such
324 as systemic diseases like diabetes.

325 NSPT is an effective form of removing pathogenic bacteria from the periodontium, which
326 promotes the healing process. However, the healing process in Type II Diabetes Mellitus
327 is more complicated as it is dependent on the level of glycemic control. Research has
328 shown with each 1% reduction in HbA1c levels the risk for Diabetes Mellitus
329 Complications decrease.²⁴ Numerous studies have investigated NSPT on glycaemic
330 control, but the evidence is often conflicting and inconsistent. Some evidence shows
331 positive effects on glycemic control, whereas other researchers have reported NSPT has
332 no effect on glycemic control, besides the improvement on the periodontium.²⁵ Three
333 studies in this review demonstrated an improvement in HbA1c levels across all groups.
334 Two papers^{17,18} showed a statistically significant difference ($p < 0.05$) favouring the
335 experimental group compared to control. A review by Engebretson et al.²⁶ observed a
336 modest reduction in HbA1c levels; however, it concluded that there was limited
337 confidence due to small sample sizes. Other studies have suggested the reduction in
338 HbA1c after NSPT is due to a decrease in the inflammatory burden of pro-inflammatory
339 cytokines such as IL-1 β , IL-6 and TNF- α .²⁷ This finding is consistent with an earlier study
340 by Christgau et al.²⁸ which observed that non-surgical periodontal therapy (NSPT)
341 facilitated metabolic control and improved insulin sensitivity by reducing levels of
342 inflammatory cytokines. This raises the issue for further research into the potential benefit
343 of using host modulation therapy as an adjunct to NSPT for diabetics in improving
344 glycaemic control.

345

346

347

348 **4.2 Quality of the evidence**

349 In this review, two RCTs were considered to have low risk of bias according to the revised
350 Cochrane risk of bias tool for randomised trials (RoB 2). Whereas the third RCT scored
351 some concerns due to selective reporting of how randomisation and blinding were
352 performed. Randomisation methods reported in this review varied and included a simple
353 coin toss and block randomisation. The CONSORT group for reporting clinical trials²⁹,
354 however, does not endorse coin tossing as a method of randomisation in an RCT, as it
355 can introduce potential bias. All three RCTs had a control group with a placebo
356 intervention, but only two of these studies^{16,18} gave information on the contents of the
357 placebo used. This could introduce another potential limitation, as the composition of a
358 placebo should be identified in order to determine its influence on the outcome.³⁰ In the
359 three studies reviewed, the NSPT approach varied among the participants in terms of
360 frequency, and it remains unclear whether these differences in treatment approach
361 influenced the clinical outcomes observed.

362

363 The studies included in this review acknowledged certain limitations in their own research.
364 These limitations highlighted the need for larger sample sizes and well-designed multi-
365 centre studies to provide more robust evidence. One study reported the true benefit of
366 omega-3 and aspirin as an adjunct to NSPT may have surfaced if the intervention had
367 been given for a longer duration. It is evident that the anti-inflammatory effects of this
368 intervention are dose and time dependent. Higher doses of omega-3 and aspirin given
369 for a longer duration have shown to exhibit greater efficacy²³, which is proven by one
370 study included in this review which saw a reduction in the measured

371 parameters. However, there are certain drawbacks associated with the use of aspirin and
372 omega-3. Prolonged usage of NSAIDs and high doses of omega-3 have the potential for
373 haemorrhage and gastro-intestinal upset.³¹

374

375 **4.3 Potential limitations in the review process**

376 This review aimed to only investigate the effect of omega-3 and aspirin on diabetic
377 patients. Nonetheless, the comprehensive search strategy uncovered three papers
378 allowing full confidence that all the relevant research was included in this review. English
379 language papers were specified in the inclusion criteria, which could have introduced
380 language bias in this review.

381

382 **4.4 Implications for practice**

383 Current guidelines in the United Kingdom state that NSAIDs and omega-3 given
384 individually as an adjunct to NSPT are not recommended. However, Sanz et al.³²
385 suggests that a combination of omega-3 and low-dose aspirin warrants further
386 assessment in managing periodontitis. This viewpoint aligns with the opinions of other
387 researchers such as Geisinger et al.³³ and Kruse et al.³⁰ who emphasise the need for
388 future studies to investigate the use of adjunctive aspirin therapy and omega-3, either
389 individually or in combination, as adjuncts to NSPT in periodontitis patients. These studies
390 highlight the potential value of exploring these interventions further to enhance
391 periodontal treatment outcomes.

392

393 **4.5 Implications for future research**

394 Despite NSPT being the focus for successful treatment outcomes in periodontitis, adjunct
395 HMT could be indicated in the presence of systemic disease such as diabetes, where
396 NSPT alone may not be enough to decrease clinical, biochemical, and metabolic
397 parameters. Future studies in primary care may be more favourable and should consider
398 or address the methodological limitations of the current published literature. Other
399 recommendations for future research include well-designed RCTs with more uniformity
400 assessing the dosage and duration of the intervention. Evidence reported in clinical trials
401 would be improved by following the CONSORT guidelines.

402

403 **5. CONCLUSION**

404 Omega-3 and aspirin have the potential to decrease clinical parameters and inflammatory
405 markers in the GCF. When administered as an adjunct to NSPT may also improve
406 glycemic control and contribute to the management of type II diabetes. However, it is
407 evident that there were conflicting results as not every paper demonstrated a statistically
408 significant difference in each outcome. As discussed, possible reasons for these results
409 may include the intervention being dose-duration dependent, small sample sizes, and
410 limited evidence currently available. Therefore, due to the uncertainty and limited
411 availability of clinical data at present, there is insufficient evidence to support the use of
412 omega-3 and aspirin as adjuncts to periodontitis in Type II Diabetes Mellitus. Further
413 research addressing the limitations of the current literature is needed.

414

415 **5.1 Implications for Clinical Practice**

416 The potential benefits of omega-3 and aspirin as adjuncts to NSPT include reductions in
417 periodontal clinical parameters and inflammatory markers, improving periodontal health
418 and possibly glycaemic control. However, inconsistent results and limited evidence mean
419 that their integration into clinical practice should be approached cautiously and requires
420 further validation.

421

422 **5.2 Implications for Research**

423 Future research should focus on addressing current limitations, including small sample
424 sizes, varying dosages and durations, and inconsistent reporting. Well-designed
425 randomised controlled trials with greater uniformity are necessary to clarify the efficacy of
426 these adjuncts and provide stronger clinical recommendations.

427

428 **ACKNOWLEDGMENTS**

429 No additional acknowledgments beyond those of the authors have been made.

430

431 **CONFLICT OF INTEREST STATEMENT**

432 The authors declare no conflicts of interest.

433

434

435

436 REFERENCES

- 437 1. Wu C zhou, Yuan Y hang, Liu H hang, Li S sui, Zhang B wen, Chen W, et al.
438 Epidemiologic relationship between periodontitis and type 2 diabetes mellitus. BMC
439 Oral Health. 2020;20:1–15.
- 440 2. Donos N, Calciolari E, Brusselaers N, Goldoni M, Bostanci N, Belibasakis GN. The
441 adjunctive use of host modulators in non-surgical periodontal therapy. A systematic
442 review of randomized, placebo-controlled clinical studies. J Clin Periodontol.
443 2020;47:199–238.
- 444 3. Eaton KA, Ower P. Practical Periodontics-E-Book. Elsevier Health Sciences; 2022.
- 445 4. Digital NHS. Adult Dental Health Survey 2009–Summary report and thematic
446 series. 2011;
- 447 5. Casanova L, Hughes FJ, Preshaw PM. Diabetes and periodontal disease: a two-
448 way relationship. Br Dent J. 2014;217(8):433–7.
- 449 6. Mealey BL, Ocampo GL. Diabetes mellitus and periodontal disease. Periodontol
450 2000. 2007;44(1):127–53.
- 451 7. World Health Organization. Diabetes [Internet]. 2023 [cited 2024 Jan 16]. Available
452 from: <https://www.who.int/news-room/fact-sheets/detail/diabetes>
- 453 8. Chee B, Park B, Bartold MP. Periodontitis and type II diabetes: a two-way
454 relationship. JBI Evid Implement. 2013;11(4):317–29.
- 455 9. Gehrig JS, Shin DE, Willmann DE. Foundations of Periodontics for the Dental
456 Hygienist, Enhanced. Jones & Bartlett Learning; 2020.

- 457 10. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.
458 The PRISMA 2020 statement: an updated guideline for reporting systematic
459 reviews. *International journal of surgery*. 2021;88:105906.
- 460 11. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile
461 app for systematic reviews. *Syst Rev*. 2016;5:1–10.
- 462 12. Park CU, Kim HJ. Measurement of inter-rater reliability in systematic review.
463 *Hanyang Medical Reviews*. 2015;35(1):44–9.
- 464 13. Bormann I. Digitizelt plot digitizer software. Digitize graphs, charts and math
465 data[WWW Document] URL <http://www.digitizeit.de/>(accessed 11/7/2017). 2017;
- 466 14. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB
467 2: a revised tool for assessing risk of bias in randomised trials. *bmj*. 2019;366.
- 468 15. Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al.
469 Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline.
470 *bmj*. 2020;368.
- 471 16. Elwakeel NM, Hazaa HH. Effect of omega 3 fatty acids plus low-dose aspirin on
472 both clinical and biochemical profiles of patients with chronic periodontitis and type
473 2 diabetes: a randomized double blind placebo-controlled study. *J Periodontol Res*.
474 2015;50(6):721–9.
- 475 17. Castro dos Santos NC, Andere NMRB, Araujo CF, de Marco AC, Kantarci A, Van
476 Dyke TE, et al. Omega-3 PUFA and aspirin as adjuncts to periodontal debridement
477 in patients with periodontitis and type 2 diabetes mellitus: randomized clinical trial.
478 *J Periodontol*. 2020;91(10):1318–27.

- 479 18. Rampally P, Koduganti RR, Ganapathi SN, Panthula VR, Surya PJ. Comparison of
480 effectiveness of low-dose aspirin versus omega-3 fatty acids as adjuvants to
481 nonsurgical periodontal therapy in Type II diabetic patients with chronic
482 periodontitis. *J Indian Soc Periodontol.* 2019;23(3):249.
- 483 19. El-Sharkawy H, Aboelsaad N, Eliwa M, Darweesh M, Alshahat M, Kantarci A, et al.
484 Adjunctive treatment of chronic periodontitis with daily dietary supplementation with
485 omega-3 fatty acids and low-dose aspirin. *J Periodontol.* 2010;81(11):1635–43.
- 486 20. Stadler AF, Angst PDM, Arce RM, Gomes SC, Oppermann R V, Susin C. Gingival
487 crevicular fluid levels of cytokines/chemokines in chronic periodontitis: a meta-
488 analysis. *J Clin Periodontol.* 2016;43(9):727–45.
- 489 21. Alexander DCC, Martin JC, King PJ, Powell JR, Caves J, Cohen ME. Interleukin-1
490 beta, prostaglandin E2, and immunoglobulin G subclasses in gingival crevicular
491 fluid in patients undergoing periodontal therapy. *J Periodontol.* 1996;67(8):755–62.
- 492 22. Telgi RL, Tandon V, Tangade PS, Tirth A, Kumar S, Yadav V. Efficacy of
493 nonsurgical periodontal therapy on glycaemic control in type II diabetic patients: a
494 randomized controlled clinical trial. *J Periodontal Implant Sci.* 2013;43(4):177–82.
- 495 23. Balta MG, Papathanasiou E, Blix IJ, Van Dyke TE. Host modulation and treatment
496 of periodontal disease. *J Dent Res.* 2021;100(8):798–809.
- 497 24. Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA, et al.
498 Association of glycaemia with macrovascular and microvascular complications of
499 type 2 diabetes (UKPDS 35): prospective observational study. *Bmj.*
500 2000;321(7258):405–12.

- 501 25. Teshome A, Yitayeh A. The effect of periodontal therapy on glycemic control and
502 fasting plasma glucose level in type 2 diabetic patients: systematic review and
503 meta-analysis. *BMC Oral Health*. 2017;17(1):1–11.
- 504 26. Engebretson S, Kocher T. Evidence that periodontal treatment improves diabetes
505 outcomes: a systematic review and meta-analysis. *J Clin Periodontol*.
506 2013;40:S153–63.
- 507 27. Jones JA, Miller DR, Wehler CJ, Rich SE, Krall-Kaye EA, McCoy LC, et al. Does
508 periodontal care improve glycemic control? The department of veterans affairs
509 dental diabetes study. *J Clin Periodontol*. 2007;34(1):46–52.
- 510 28. Christgau M, Palitzsch K, Schmalz G, Kreiner U, Frenzel S. Healing response to
511 non-surgical periodontal therapy in patients with diabetes mellitus: clinical,
512 microbiological, and immunologic results. *J Clin Periodontol*. 1998;25(2):112–24.
- 513 29. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines
514 for reporting parallel group randomised trials. *BMJ*. 2010 Mar 23;340(mar23
515 1):c332–c332.
- 516 30. Kruse AB, Kowalski CD, Leuthold S, Vach K, Ratka-Krüger P, Woelber JP. What is
517 the impact of the adjunctive use of omega-3 fatty acids in the treatment of
518 periodontitis? A systematic review and meta-analysis. *Lipids Health Dis*.
519 2020;19:1–16.
- 520 31. Elkhoul AM. The efficacy of host response modulation therapy (omega-3 plus low-
521 dose aspirin) as an adjunctive treatment of chronic periodontitis (clinical and
522 biochemical study). *J Periodontal Res*. 2011;46(2):261–8.

- 523 32. Sanz M, Herrera D, Kebschull M, Chapple I, Jepsen S, Berglundh T, et al.
524 Treatment of stage I–III periodontitis—The EFP S3 level clinical practice guideline.
525 J Clin Periodontol. 2020;47:4–60.
- 526 33. Geisinger ML, Holmes CM, Vassilopoulos PJ, Geurs NC, Reddy MS. Adjunctive
527 treatment of chronic periodontitis with systemic low-dose aspirin therapy. Clin Adv
528 Periodontics. 2012;2(3):195–9.
- 529